Biodistribution and anti-tumor efficacy of intratumorally injected necrosis-avid theranostic agent radioiodinated hypericin in rodent tumor models

References

• Chopra A. Radioiodinated anti-DNA-histone 1 complex chimeric tumor necrosis therapy (TNT) monoclonal antibody 1. Molecular Imaging and Contrast Agent Database (MICAD)-NCBI Bookshelf [WWW document]; 2011. Available from: http://www.ncbi.nlm.nih.gov/books/NBK82385 [last accessed 12 Dec 2014]
   Google Scholar
• Cooper E, Bedford A, Kenny T. Cell death in normal and malignant tissues. Adv Cancer Res 1975;21:59–120
   PubMedGoogle Scholar
• Koljenović S, Lin-P'ing Choo-Smith T, Schut CB, et al. Discriminating vital tumor from necrotic tissue in human glioblastoma tissue samples by Raman spectroscopy. Lab Investig 2002;82:1265–77
   PubMed Web of Science ®Google Scholar
• Tufto I, Rofstad EK. Interstitial fluid pressure, fraction of necrotic tumor tissue, and tumor cell density in human melanoma xenografts. Acta Oncologica 1998;37:291–7
   PubMed Web of Science ®Google Scholar
• Epstein AL, Chen F-M, Taylor CR. A novel method for the detection of necrotic lesions in human cancers. Cancer Res 1988;48:5842–8
   PubMed Web of Science ®Google Scholar
• Chen F-M, Taylor CR, Epstein AL. Tumor necrosis treatment of ME-180 human cervical carcinoma model with 131I-labeled TNT-1 monoclonal antibody. Cancer Res 1989;49:4578–85
   PubMed Web of Science ®Google Scholar
• Khawli LA, Hu P, Epstein AL. Multiple uses of tumor necrosis therapy (TNT) for the treatment and imaging of solid tumors: preclinical considerations and progress. Update Cancer Therapeut 2006;1:33–47
   Google Scholar
• Cona MM, Wang H, Li J, et al. Continuing pursuit for ideal systemic anticancer radiotherapeutics. Investig New Drugs 2012;30:2050–65
   PubMed Web of Science ®Google Scholar
• Liu W, MacKay JA, Dreher MR, et al. Injectable intratumoral depot of thermally responsive polypeptide–radionuclide conjugates delays tumor progression in a mouse model. J Control Rel 2010;144:2–9
   PubMed Web of Science ®Google Scholar
• Celikoglu F, Celikoglu SI, York AM, Goldberg EP. Intratumoral administration of cisplatin through a bronchoscope followed by irradiation for treatment of inoperable non-small cell obstructive lung cancer. Lung Cancer 2006;51:225–36
   PubMed Web of Science ®Google Scholar
• Nakase Y, Hagiwara A, Kin S, et al. Intratumoral administration of methotrexate bound to activated carbon particles: antitumor effectiveness against human colon carcinoma xenografts and acute toxicity in mice. J Pharmacol Exp Therapeut 2004;311:382–87
   PubMed Web of Science ®Google Scholar
• van Herpen CM, van der Laak JA, de Vries IJM, et al. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor. Clin Cancer Res 2005;11:1899–909
   PubMed Web of Science ®Google Scholar
• Yunchun L, Tianzhi T, Weiyun X, Sheng H. 131I-Recombinant human EGF has anti-tumor effects against MCF-7 human breast cancer xenografts with low levels of EGFR. Nucl Med Biol 2004;31:435–40
   PubMed Web of Science ®Google Scholar
• Vriesendorp HM, Quadri SM. Radiolabeled immunoglobulin therapy: old barriers and new opportunities. Expert Rev Anticancer Therap 2001;1:461–78
   PubMedGoogle Scholar
• Karioti A, Bilia AR. Hypericins as potential leads for new therapeutics. Int J Mol Sci 2010;11:562–94
   PubMed Web of Science ®Google Scholar
• Van de Putte M, Wang H, Chen F, et al. Hypericin as a marker for determination of tissue viability after intratumoral ethanol injection in a murine liver tumor model. Acad Radiol 2008;15:107–13
   PubMed Web of Science ®Google Scholar
• Van de Putte M, Wang H, Chen F, et al. Hypericin as a marker for determination of tissue viability after radiofrequency ablation in a murine liver tumor model. Oncol Rep 2008;19:927–32
   PubMed Web of Science ®Google Scholar
• Van de Putte M, Ni Y, De Witte PA. Exploration of the mechanism underlying the tumor necrosis avidity of hypericin. Oncol Rep 2008;19:921–6
   PubMed Web of Science ®Google Scholar
• Bormans G, Marchal G, Verbruggen A, Yicheng N. U.S. Patent Application 10/595,062[P]. 2004-7-23
   Google Scholar
• Li J, Sun Z, Zhang J, et al. A dual-targeting anticancer approach: soil and seed principle. Radiology 2011;260:799–807
   PubMed Web of Science ®Google Scholar
• Li J, Cona MM, Chen F, et al. Exploring theranostic potentials of radioiodinated hypericin in rodent necrosis models. Theranostics 2012;2:1010–19
   PubMed Web of Science ®Google Scholar
• Li J, Cona MM, Chen F, et al. Sequential systemic administrations of combretastatin A4 Phosphate and radioiodinated hypericin exert synergistic targeted theranostic effects with prolonged survival on SCID mice carrying bifocal tumor xenografts. Theranostics 2013;3:127–37
   PubMed Web of Science ®Google Scholar
• Van de Putte M, Marysael T, Fonge H, et al. Radiolabeled iodohypericin as tumor necrosis avid tracer: diagnostic and therapeutic potential. Int J Cancer 2012;131:E129–37
   PubMed Web of Science ®Google Scholar
• Clarke K, Lee F-T, Brechbiel MW, et al. In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice. Cancer Res 2000;60:4804–11
   PubMed Web of Science ®Google Scholar
• Sun Z, Ni Y. Iodogen method for preparation of radioiodinated hypericin. Patent CN 200910013998; 2009
   Google Scholar
• Fonge H, Vunckx K, Wang H, et al. Non-invasive detection and quantification of acute myocardial infarction in rabbits using MONO-[123I] iodohypericin µSPECT. Eur Heart J 2008;29:260–9
   PubMed Web of Science ®Google Scholar
• Ni Y, Bormans G, Chen F, et al. Necrosis avid contrast agents: functional similarity versus structural diversity. Investig Radiol 2005;40:526–35
   PubMed Web of Science ®Google Scholar
• Ni Y. Metalloporphyrins and functional analogues as MRI contrast agents. Curr Med Imag Rev 2008;4:96–112
   Web of Science ®Google Scholar
• Ni Y, Adzamli K, Miao Y, et al. MRI contrast enhancement of necrosis by MP-2269 and gadophrin-2 in a rat model of liver infarction. Investig Radiol 2001;36:97–103
   PubMed Web of Science ®Google Scholar
• Ni Y. MR Contrast agents for cardiac imaging. Clinical cardiac MRI. Berlin - Heidelberg: Springer; 2012:31–51
   Google Scholar
• Li J, Oyen R, Verbruggen A, Ni Y. Small molecule sequential dual targeting theragnostic strategy (SMSDTTS): from preclinical experiments towards possible clinical anticancer applications. J Cancer 2013;4:133–45
   PubMed Web of Science ®Google Scholar
• Wang H, Wu X, Chen F, et al. Development, evaluation and application of reperfused liver infarction in rats as a practical model for studying ischemic diseases and screening new drugs. Int J Model Identif Contr 2010;9:247–61
   Google Scholar
• Bormans G, Huyghe D, Christiaen A, et al. Preparation, analysis and biodistribution in mice of iodine 123 labelled derivatives of hypericin. J Label Comp Radiopharmaceutical 2004;47:191–8
   Web of Science ®Google Scholar
• Ni Y, Huyghe D, Verbeke K, et al. First preclinical evaluation of mono-[123I] iodohypericin as a necrosis-avid tracer agent. Eur J Nucl Med Mol Imag 2006;33:595–601
   PubMed Web of Science ®Google Scholar